| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | -0.029 | 0.7 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |